source
- AI monitoring tool could generate up to 82-fold ROI in phase-3 oncology trials, study findsAn analysis by the Tufts Center for the Study of Drug Development found that an artificial-intelligence clinical monitoring agent can produce an estimated 82-fold return on investment in phase-3 on…
- Former Pfizer chemist launches Khartis Therapeutics with $95M to develop oral thyroid eye disease drugRobert Hoffman, a veteran Pfizer chemist who previously co‑founded XinThera, announced the launch of Khartis Therapeutics. The new company, formed in 2024 with other former XinThera leaders, aims t…